Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the French POLA cohort
Published date:
02/01/2021
Excerpt:
The 4‐year PFS in the RT + PCV arm was 70.8% versus 53.5% in the RT + TMZ arm...RT + PCV significantly improved PFS compared with RT + TMZ for IDH‐mutant AA.